Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True?
作者信息
Siedner Mark J
机构信息
Harvard Medical School, Boston, Massachusetts, USA.
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
出版信息
Open Forum Infect Dis. 2021 Jun 14;8(11):ofab318. doi: 10.1093/ofid/ofab318. eCollection 2021 Nov.
Abstract
摘要
相似文献
1
Ivermectin for the Treatment of COVID-19 Disease: Too Good to Pass Up or Too Good to Be True?伊维菌素用于治疗新冠疾病：好到不容错过还是好到难以置信？
Open Forum Infect Dis. 2021 Jun 14;8(11):ofab318. doi: 10.1093/ofid/ofab318. eCollection 2021 Nov.
2
Intravenous veterinary ivermectin in a COVID-19 patient causing neurotoxicity.静脉注射兽用伊维菌素致一名新冠肺炎患者发生神经毒性
IDCases. 2022;27:e01446. doi: 10.1016/j.idcr.2022.e01446. Epub 2022 Feb 7.
3
Prophylactic Role of Ivermectin in Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Healthcare Workers.伊维菌素在医护人员严重急性呼吸综合征冠状病毒2感染中的预防作用
Cureus. 2021 Aug 5;13(8):e16897. doi: 10.7759/cureus.16897. eCollection 2021 Aug.
4
Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching.用于COVID-19的伊维菌素预防：一项对223,128名受试者进行倾向评分匹配的全市前瞻性观察研究。
Cureus. 2022 Jan 15;14(1):e21272. doi: 10.7759/cureus.21272. eCollection 2022 Jan.
5
The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis.伊维菌素的使用与 COVID-19 患者死亡率之间的关联：一项荟萃分析。
Pharmacol Rep. 2021 Oct;73(5):1473-1479. doi: 10.1007/s43440-021-00245-z. Epub 2021 Mar 29.
6
Ivermectin treatment for infection in patients with COVID-19.伊维菌素治疗新型冠状病毒肺炎患者的感染情况。
Can Commun Dis Rep. 2021 Jul 8;47(7-8):316-321. doi: 10.14745/ccdr.v47i78a04.
7
Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response.自我处方伊维菌素的使用与 COVID 确诊医护人员的血清转化率降低有关，且呈剂量依赖性反应。
Braz J Infect Dis. 2021 Jul-Aug;25(4):101603. doi: 10.1016/j.bjid.2021.101603. Epub 2021 Aug 12.
8
Ivermectin for onchocercal eye disease (river blindness).用于治疗盘尾丝虫性眼病（河盲症）的伊维菌素。
Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD002219. doi: 10.1002/14651858.CD002219.pub2.
9
Chemoprophylaxis against COVID-19 among health-care workers using Ivermectin in low- and middle-income countries: A systematic review and meta-analysis.伊维菌素用于中低收入国家医护人员的 COVID-19 化学预防：系统评价和荟萃分析。
Indian J Pharmacol. 2021 Nov-Dec;53(6):493-498. doi: 10.4103/ijp.ijp_117_21.
10
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial.单剂量口服伊维菌素治疗轻中度 COVID-19（RIVET-COV）：一项单中心随机、安慰剂对照试验。
J Infect Chemother. 2021 Dec;27(12):1743-1749. doi: 10.1016/j.jiac.2021.08.021. Epub 2021 Aug 25.
引用本文的文献
1
The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 - a double-blind, randomized placebo-controlled trial.伊维菌素对非住院轻中度 COVID-19 患者早期治疗中病毒载量和培养活力的影响：一项双盲、随机、安慰剂对照试验。
Int J Infect Dis. 2022 Sep;122:733-740. doi: 10.1016/j.ijid.2022.07.003. Epub 2022 Jul 8.
2
Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?2019年冠状病毒病（COVID-19）的治疗选择：我们目前的进展如何？
Curr Infect Dis Rep. 2021;23(12):28. doi: 10.1007/s11908-021-00769-8. Epub 2021 Dec 11.
3
Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients.伊维菌素和阿托伐他汀对 SARS-CoV-2 阳性患者鼻咽拭子中宿主细胞内 Importin Alpha 核定位及药物靶标表达谱的影响。
Viruses. 2021 Oct 15;13(10):2084. doi: 10.3390/v13102084.
本文引用的文献
1
Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.综述表明伊维菌素在 COVID-19 预防和治疗中的疗效的新证据。
Am J Ther. 2021 Apr 22;28(3):e299-e318. doi: 10.1097/MJT.0000000000001377.
2
Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials.伊维菌素治疗 2019 年冠状病毒病：随机对照试验的系统评价和荟萃分析。
Clin Infect Dis. 2022 Mar 23;74(6):1022-1029. doi: 10.1093/cid/ciab591.
3
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines.伊维菌素用于预防和治疗 COVID-19 感染：系统评价、荟萃分析和试验序贯分析，为临床指南提供信息。
Am J Ther. 2021 Jun 21;28(4):e434-e460. doi: 10.1097/MJT.0000000000001402.
4
India's COVID-19 crisis: a call for international action.印度的新冠疫情危机：呼吁国际行动。
Lancet. 2021 Jun 5;397(10290):2132-2135. doi: 10.1016/S0140-6736(21)01121-1. Epub 2021 May 14.
5
From Vaccine Nationalism to Vaccine Equity - Finding a Path Forward.从疫苗民族主义到疫苗公平——探寻前进之路
N Engl J Med. 2021 Apr 8;384(14):1281-1283. doi: 10.1056/NEJMp2103614. Epub 2021 Apr 3.
6
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
7
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8.
8
COVID-19 therapeutics: how to sow confusion and break public trust during international public health emergencies.新冠病毒病（COVID-19）治疗方法：在国际突发公共卫生事件期间如何制造混乱并破坏公众信任。
J Pharm Policy Pract. 2020 Jul 24;13:47. doi: 10.1186/s40545-020-00244-0. eCollection 2020.
9
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
10
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
Zotero 插件